drugset / Trial / NCT05985083
A Study Of IMM47 In Subjects With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a first-in-human (FIH), open-label, multi-center, phase I study to evaluate the safety, tolerance, pharmacokinetics (PK), immunogenicity, preliminary anti-tumor activity, pharmacodynamics, and biomarker activity of IMM47 monotherapy in subjects with advanced solid tumors.
Timeline
- Start
- 2023-08-18
- Primary completion
- 2024-12-26
- Completion
- 2025-01-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM47 | Monoclonal antibody | 5 ug/kg | Intravenous |
| Subject | IMM47 | Monoclonal antibody | 50 ug/kg | Intravenous |
| Subject | IMM47 | Monoclonal antibody | 250 ug/kg | Intravenous |
| Subject | IMM47 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | IMM47 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | IMM47 | Monoclonal antibody | 5 mg/kg | Intravenous |
Indications
No indication recorded.